ICH GOOD CLINICAL PRACTICE (GCP) FOR CERTIFIED CLINICAL RESEARCH COORDINATOR (CCRC) PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://ichgcpforccrc.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. Which topic specifically covers issues arising when therapy is blinded during a trial?

A. How to Report

B. Fatal or Life-Threatening ADRs

C. Managing Blinded Therapy Cases

D. Minimum Criteria for Reporting

2. Post-study adverse events are typically reported by the investigator to the sponsor. true or false?

A. True

B. False

C. Not sure

D. Only for certain trials

3. When planning trials, what should the sponsor ensure regarding safety and efficacy data?

A. Safety data from nonclinical studies only are sufficient.

B. Efficacy data should be the only driver for human exposure.

C. The sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.

D. The sponsor should not rely on prior data.

4. Accrual rate refers to which aspect of a trial?

A. The rate of data entry

B. The rate of site activation

C. The rate of adverse event reporting

D. The rate at which subjects are enrolled

5. Who must sign and date the written informed consent prior to participation?

A. The signer must be the subject.

B. The subject or the subject's legally acceptable representative, and the person who conducted the consent discussion, must sign and date.

C. The sponsor must sign.

D. The IRB must sign.

SAMPLE

6. Which of the following describes the Per Protocol Set's components?

A. All randomized subjects

B. Subjects who experienced adverse events

C. Valid cases, efficacy sample, evaluable subjects

D. Subjects with missing data

7. Phase IV objectives may include which of the following?

A. Should be clearly stated and may include exploratory or confirmatory characterization of safety and/or efficacy and/or assessment of pharmacokinetic parameters

B. Only assess efficacy

C. Only assess safety

D. Only characterize pharmacodynamics

8. The plan for the scope of evaluation in a clinical trial is described by which topic?

A. Set of Subjects to be Evaluated and Presentation of Data

B. Statistical Evaluation

C. Scope of Evaluation

D. Subgroups, Interactions and Covariates

9. Which combination best describes the data transfer media used in data capture and processing?

A. Paper CRFs only

B. Remote monitoring only

C. Electronic transfer only

D. Paper case record forms, remote site monitoring systems, medical computer systems and electronic transfer

10. What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?

A. They collect all data

B. They fund the trial

C. They supervise ongoing safety and trial integrity and may recommend continuation or termination

D. They write the final manuscript

SAMPLE

Answers

SAMPLE

1. C
2. A
3. C
4. D
5. C
6. C
7. C
8. C
9. D
10. C

SAMPLE

Explanations

SAMPLE

1. Which topic specifically covers issues arising when therapy is blinded during a trial?

A. How to Report

B. Fatal or Life-Threatening ADRs

C. Managing Blinded Therapy Cases

D. Minimum Criteria for Reporting

Blinding in clinical trials aims to prevent bias, so there are specific procedures for situations where the therapy is blinded. This topic covers how to manage those cases, including when and how unblinding is allowed, who may authorize it, and how to document safety assessments without compromising the blind. It also addresses maintaining trial integrity while protecting participant safety, handling adverse events, and ensuring accurate analysis when treatment assignments are unknown. These are the issues that arise specifically because the therapy is blinded, making this the most relevant focus. General reporting or safety-reaction topics don't address the unique management of blinded therapies.

2. Post-study adverse events are typically reported by the investigator to the sponsor. true or false?

A. True

B. False

C. Not sure

D. Only for certain trials

Post-study safety reporting is a real obligation. Investigators must promptly report serious adverse events to the sponsor, and this duty continues even after a participant has completed the study if the event is related to the investigational product or study procedures. This ongoing reporting allows the sponsor to maintain a complete safety database, perform causality assessment, and fulfill regulatory reporting requirements. Not all post-study events require reporting—only those that are serious and related to the trial—but for serious adverse events, the investigator-to-sponsor reporting rule applies. Therefore, the statement is true.

3. When planning trials, what should the sponsor ensure regarding safety and efficacy data?

A. Safety data from nonclinical studies only are sufficient.

B. Efficacy data should be the only driver for human exposure.

C. The sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.

D. The sponsor should not rely on prior data.

When planning a trial, the key idea is to confirm there is enough safety and efficacy information to justify exposing humans to the investigational product. This means using data from nonclinical studies (such as animal and in vitro work) and any available clinical data, and ensuring those data support the planned route of administration, the doses, the duration of exposure, and the characteristics of the trial population. This evidence base underpins a responsible risk–benefit assessment, informs starting doses and dose-escalation schemes, guides who can participate, and shapes safety monitoring and stopping rules. Relying on safety data alone or efficacy data alone would leave important gaps, and disregarding prior data would ignore useful information. Therefore, the sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.

SAMPLE

4. Accrual rate refers to which aspect of a trial?

A. The rate of data entry

B. The rate of site activation

C. The rate of adverse event reporting

D. The rate at which subjects are enrolled

Accrual rate is about how quickly participants are enrolled into the trial. It measures enrollment pace, not data entry, site activation, or safety reporting. In study planning, you estimate how many subjects you can enroll per unit time (for example, per month) to set realistic timelines, power, and budget. If enrollment falls short of the projection, you might add sites, adjust outreach, or extend the enrollment window. The other options describe different processes: data entry speed, how fast sites come online, and how quickly adverse events are reported. So the pace of enrolling subjects best defines accrual rate.

5. Who must sign and date the written informed consent prior to participation?

A. The signer must be the subject.

B. The subject or the subject's legally acceptable representative, and the person who conducted the consent discussion, must sign and date.

C. The sponsor must sign.

D. The IRB must sign.

Understanding informed consent requires documenting the participant's voluntary agreement to participate. The written consent form must be signed and dated by the person who participates (the subject) or their legally acceptable representative, and by the person who conducted the consent discussion (usually the investigator or designated staff) to confirm they provided the study information and answered questions. If a legally authorized representative signs on behalf of someone unable to consent, they must also sign and date. The sponsor does not sign the participant's consent form; the sponsor's role is oversight and funding, not signing each consent document. The IRB reviews and approves the consent form, but does not sign the participant's consent as part of the enrollment process.

6. Which of the following describes the Per Protocol Set's components?

A. All randomized subjects

B. Subjects who experienced adverse events

C. Valid cases, efficacy sample, evaluable subjects

D. Subjects with missing data

The Per Protocol Set includes participants who followed the study protocol as intended, with no major deviations and with complete, evaluable data for the efficacy analysis. This is why it's described by terms like valid cases, efficacy sample, and evaluable subjects—the dataset is cleaned to reflect ideal adherence and complete endpoints. This differs from the full randomized population, which is analyzed to preserve randomization and generalizability (intent-to-treat). It also isn't about who had adverse events, since adverse events can occur in any adherent or non-adherent participant, and it typically excludes those with missing data, who cannot contribute to the efficacy analysis.

SAMPLE

7. Phase IV objectives may include which of the following?

A. Should be clearly stated and may include exploratory or confirmatory characterization of safety and/or efficacy and/or assessment of pharmacokinetic parameters

B. Only assess efficacy

C. Only assess safety

D. Only characterize pharmacodynamics

Phase IV trials are conducted after a drug is approved to monitor long term safety and real world risk. The central objective is ongoing safety monitoring, capturing adverse events, identifying rare or long term risks, and evaluating safety in broader patient populations. Because safety surveillance is the defining focus in the post marketing setting, an option that states the objective is to assess safety aligns best, even though some studies may also collect data on efficacy or pharmacokinetics in specific contexts. The other choices imply primary goals like efficacy or pharmacodynamics that are not the core aim of Phase IV studies.

8. The plan for the scope of evaluation in a clinical trial is described by which topic?

A. Set of Subjects to be Evaluated and Presentation of Data

B. Statistical Evaluation

C. Scope of Evaluation

D. Subgroups, Interactions and Covariates

Defining what data will be evaluated and how they will be analyzed is captured by the topic Scope of Evaluation. This area lays out the plan for which data and endpoints will be included, which timepoints are relevant, and which analysis populations (for example, the full analysis set or per-protocol set) will be used. It essentially draws the boundaries of the statistical evaluation so the plan is clear before any analysis is done. Understanding this helps ensure the analysis is pre-specified and objective, rather than shaped after seeing the results. The other topics govern how the data are analyzed (Statistical Evaluation), who is included and how data are summarized (Set of Subjects to be Evaluated and Presentation of Data), and what additional insights might be explored (Subgroups, Interactions and Covariates), but the plan for what falls inside the scope of evaluation itself is described by Scope of Evaluation.

9. Which combination best describes the data transfer media used in data capture and processing?

A. Paper CRFs only

B. Remote monitoring only

C. Electronic transfer only

D. Paper case record forms, remote site monitoring systems, medical computer systems and electronic transfer

Data capture and processing rely on a mix of media to collect, move, and verify trial data. Paper CRFs are still used for initial data collection at sites, while electronic transfer and electronic data capture enable fast, secure transmission to central data processing systems. Remote site monitoring systems and medical computer systems can also generate or relay data to sponsors and monitors, supporting ongoing data integrity and timely review. This combination best reflects the real-world mix of media involved in capturing and processing clinical trial data, whereas other options describe just a single method.

SAMPLE

10. What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?

A. They collect all data

B. They fund the trial

C. They supervise ongoing safety and trial integrity and may recommend continuation or termination

D. They write the final manuscript

The main idea is that the DMC/DSMB provides independent, ongoing safety and trial integrity oversight as data accumulate. They review the accumulating data from the clinical trial—especially safety signals and data quality—using predefined stopping rules and interim analyses. Based on what they find, they may recommend continuation or termination of the trial to protect participants and preserve credible results. They aren't responsible for collecting data (that's the data management team), funding the trial (the sponsor), or writing the final manuscript (the investigators/authors). The DMC's role is to watch over safety and integrity and advise on whether the trial should continue.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://ichgcpforccrc.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE